Clinic Roundup
Soricimed Biopharma Inc., of Toronto, initiated the Phase I trial of its anticancer agent SOR-C13. The multicenter, open-label, dose-escalation study is designed to assess safety and tolerability in patients with advanced cancer tumors, with a weighting on ovarian cancers.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.